Welcome to our dedicated page for Biotricity news (Ticker: BTCY), a resource for investors and traders seeking the latest updates and insights on Biotricity stock.
Biotricity Inc. (BTCY) delivers innovative medical technology solutions focused on AI-powered cardiac monitoring and chronic disease management. This news hub provides investors and healthcare professionals with essential updates on the company’s advancements in remote patient care.
Access timely press releases covering regulatory milestones, clinical study results, and strategic partnerships with healthcare institutions. Stay informed about product developments like the Bioflux cardiac monitoring system and consumer-focused Biolife platform, which combine medical-grade accuracy with AI-driven analytics.
Our curated news collection features earnings reports, technology patent announcements, and market expansion updates. Bookmark this page for verified information about BTCY’s progress in transforming cardiac care through connected health solutions.
Biotricity, Inc. (NASDAQ:BTCY) has successfully closed an underwritten public offering, raising approximately $15 million by selling 5 million shares at $3.00 each. The underwriter has a 30-day option to buy an additional 750,000 shares. Proceeds from the offering will be allocated for general corporate purposes, including working capital and potential acquisitions. This offering was conducted under an effective registration statement declared by the SEC. Biotricity focuses on remote health monitoring solutions for chronic care management.
Biotricity Inc. (BTCY) announced a public offering of 5,000,000 shares of common stock, priced at $3.00 per share, totaling approximately $15 million in gross proceeds. The offering includes a 30-day option for the underwriter to purchase an additional 750,000 shares. The closing is expected on August 30, 2021, with shares listed on the Nasdaq Capital Market as of August 26, 2021. H.C. Wainwright & Co. is the sole book-running manager. The shares are offered through a prospectus filed with the SEC.
Biotricity (OTCQB:BTCY) has announced plans for an underwritten public offering of its common stock as it prepares for a potential listing on the Nasdaq Capital Market. The offering will include a 30-day option for the underwriter to purchase additional shares. Funds raised will support general corporate purposes like working capital and acquisitions. The offering is subject to market conditions and is made under an effective shelf registration statement filed with the SEC.
Biotricity (OTCQB:BTCY) has reported impressive results for Q1 of fiscal 2022, marking a record revenue of $1.76 million, representing a 290% year-over-year growth, the ninth consecutive quarter of triple-digit growth. This also reflects a 49% sequential increase compared to the previous quarter. Operating expenses grew modestly by 17% to $4.2 million, indicating the scalability of their business model. The company awaits FDA approval for its new Biotres holter product, poised for a swift launch. Future revenue growth is projected as the company continues to expand its market presence.
Biotricity (OTCQB:BTCY) plans to release its financial results for the first quarter of fiscal 2022 on August 16, 2021, after market close. A conference call and live webcast will be held on the same day at 1:30 p.m. PT to discuss the results. Investors can access the call at +1 334-777-6978 or 800-367-2403 using the passcode 7356128. For online access, a link will be available on their website. The company focuses on remote monitoring and chronic care management in healthcare.
Biotricity, Inc. (OTCQB:BTCY) announced preliminary revenue guidance for its fiscal Q1 2022, indicating a record growth quarter. The company expects a revenue increase of over 45% from the prior quarter and more than 280% year-over-year, marking its 9th consecutive quarter of growth. Management anticipates adding new cardiology customers quarterly, expanding from 17 to 23 states. Despite potential pandemic impacts, the company expects continued triple-digit revenue growth for the remainder of the year.
Biotricity, Inc. (OTCQB:BTCY) reported strong financial results for Q4 and fiscal year 2021, with Q4 revenue reaching $1.2 million, reflecting an 8th consecutive quarter of triple-digit year-over-year growth. This quarter saw a 227% increase in revenue, surpassing the previous quarter's 162%. The annual revenue totaled $3.4 million, up 139% from fiscal 2020. Despite a net loss of $16.2 million, management anticipates further growth, targeting triple-digit revenue increases for fiscal 2022.
Biotricity, Inc. (OTCQB:BTCY) will release its financial results for the fourth quarter and full fiscal year 2021, ending March 31, 2021, on June 15, 2021, post-market close. A live conference call will occur at 1:30 p.m. PT (4:30 p.m. ET) on the same day to discuss these results. Interested parties can join via phone at +1 334-777-6978 or toll-free at 800-367-2403, using passcode 3169700. Additionally, a webcast will be available on the company's website for further access and replay.
Biotricity Inc. (BTCY) announced that CEO Waqaas Al-Siddiq will present at the LD Micro Invitational XI on June 8, 2021, at 11:30 a.m. EDT. The presentation will focus on the company's vision for diagnostic solutions and an update on growth following record fiscal 2021 results. Attendees can register for the presentation here. Following the event, management will hold one-on-one virtual meetings on June 8 and 9. The LD Micro Invitational will feature approximately 180 companies and influential keynote speakers.
Biotricity, Inc. (OTCQB:BTCY) has initiated its strategy to uplist to a major exchange in 2021, highlighting its commitment to enhance shareholder value. The company has submitted an application for listing, aiming to align its capital needs with growth potential in a market exceeding $3 billion in annual sales. CEO Waqaas Al-Siddiq reaffirmed the company's plans to broaden its investor base and capitalize on market opportunities as they progress towards uplisting.
